MA27181A1 - Derives de thiazole et d'oxazole qui modulent l'activite de ppar. - Google Patents

Derives de thiazole et d'oxazole qui modulent l'activite de ppar.

Info

Publication number
MA27181A1
MA27181A1 MA27839A MA27839A MA27181A1 MA 27181 A1 MA27181 A1 MA 27181A1 MA 27839 A MA27839 A MA 27839A MA 27839 A MA27839 A MA 27839A MA 27181 A1 MA27181 A1 MA 27181A1
Authority
MA
Morocco
Prior art keywords
ppar
activity
compounds
thiazole
modulate
Prior art date
Application number
MA27839A
Other languages
English (en)
Inventor
Xue-Min Cheng
Gary Frederick Filzen
Chitase Lee
Noe Ouano Erasga
Andrew George Geyer
Bharat Kalidas Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA27181A1 publication Critical patent/MA27181A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DEPOSANT Société dite : WARNER-LAMBERT COMPANY LLC REVENDICATION DE PRIORITES US 7 Mars 2002 60/362,402 Voir en annexe le titre de l'invention et le texte de l'abrégé Dérivés de thiazole et d'oxazole qui modulent l'activité de PPAR La présente invention fait connaître des composés qui modifient l'activité de PPAR. La présente invention fait connaître également des sels pharmaceutiquement acceptables des composés, des compositions pharmaceutiquement acceptables comprenant les composés ou leurs sels, et des méthodes pour leur utilisation comme agents thérapeutiques à des fins de traitement ou de prévention de l'hyperlipidémie et de l'hypercholestérolémie chez un mammifère. La présente invention fait connaître également des procédés pour la préparation des composés décrits.
MA27839A 2002-03-07 2004-08-30 Derives de thiazole et d'oxazole qui modulent l'activite de ppar. MA27181A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36240202P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
MA27181A1 true MA27181A1 (fr) 2005-01-03

Family

ID=27789157

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27839A MA27181A1 (fr) 2002-03-07 2004-08-30 Derives de thiazole et d'oxazole qui modulent l'activite de ppar.

Country Status (29)

Country Link
US (1) US20030207924A1 (fr)
EP (1) EP1482935B1 (fr)
JP (1) JP2005528348A (fr)
KR (1) KR20040091693A (fr)
AP (1) AP2004003124A0 (fr)
AR (1) AR038881A1 (fr)
AT (1) ATE405260T1 (fr)
AU (1) AU2003206059A1 (fr)
BR (1) BR0308277A (fr)
CA (1) CA2478520A1 (fr)
CO (1) CO5601012A2 (fr)
DE (1) DE60323060D1 (fr)
EA (1) EA200400943A1 (fr)
EC (1) ECSP045285A (fr)
ES (1) ES2310650T3 (fr)
HN (1) HN2003000090A (fr)
IS (1) IS7377A (fr)
MA (1) MA27181A1 (fr)
MX (1) MXPA04007564A (fr)
NO (1) NO20044242L (fr)
OA (1) OA12780A (fr)
PA (1) PA8567801A1 (fr)
PE (1) PE20030989A1 (fr)
PL (1) PL372969A1 (fr)
TN (1) TNSN04168A1 (fr)
TW (1) TW200305403A (fr)
UY (1) UY27695A1 (fr)
WO (1) WO2003074050A1 (fr)
ZA (1) ZA200406068B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
SI1638551T1 (sl) * 2003-05-19 2012-04-30 Irm Llc Imunosupresivne spojine in sestavki
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
CN1946666A (zh) 2004-02-27 2007-04-11 埃姆艮股份有限公司 用于治疗代谢性疾病的化合物、药物组合物和方法
WO2005105736A1 (fr) 2004-05-05 2005-11-10 Novo Nordisk A/S Nouveaux composes, leur preparation et leur utilisation
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ZA200610650B (en) * 2004-05-25 2009-04-29 Metabolex Inc Substituted triazoles as modulators of PPAR and methods of their preparation
JP2008500358A (ja) * 2004-05-25 2008-01-10 メタボレックス インコーポレーティッド Ｐｐａｒのモジュレーターとしての、二環式の置換されたトリアゾール、およびこれらの調製方法
WO2006121223A1 (fr) * 2005-05-07 2006-11-16 Heon Joong Kang Procede pour preparer des ligands de ppardelta et les composes intermediaires pour preparer ceux-ci
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
KR101333101B1 (ko) 2005-06-30 2013-11-26 하이 포인트 파마슈티칼스, 엘엘씨 Ｐｐａｒ-델타 활성제로서의 페녹시 아세트산
EP1916234B1 (fr) * 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Composé d'acide cyclopropanecarboxylique
CA2621949A1 (fr) 2005-09-14 2007-03-22 Amgen Inc. Acides propanoiques 3-substitues par un groupement 4-hydroxyphenyle a conformation contrainte pouvant etre employes dans le traitement de troubles metaboliques
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
JP2009132620A (ja) * 2006-03-07 2009-06-18 Astellas Pharma Inc フェニルチアゾール誘導体
CA2645719A1 (fr) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Nouveaux composes, leur preparation et utilisation
CA2662242C (fr) 2006-09-07 2012-06-12 Amgen Inc. Composes benzo-fusionnes destines a etre utilises dans le traitement de troubles metaboliques
EP2064193A1 (fr) 2006-09-07 2009-06-03 Amgen, Inc Modulateurs hétérocycliques du récepteur couplé à la protéine g (gpr40)
EP2139843B1 (fr) 2007-04-16 2013-12-25 Amgen, Inc Modulateurs de gpr40 des acides biphényle phénoxy, thiophényle et aminophénylpropanoïque substitués
MX2010003876A (es) 2007-10-10 2010-12-02 Amgen Inc Moduladores de gpr40 bifenilo- sustituidos.
CA2708391A1 (fr) * 2007-12-13 2009-06-25 Sri International Ligands ppar-delta et leurs procedes d'utilisation
CN101945848A (zh) 2007-12-20 2011-01-12 英维沃医药有限公司 四取代的苯
EP2260017A1 (fr) 2008-03-06 2010-12-15 Amgen, Inc Dérivés d'acide carboxylique conformationnellement dépendants, utiles dans le traitement de troubles du métabolisme
US8748462B2 (en) 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
EP2540711A4 (fr) * 2010-02-25 2014-01-22 Snu R&Db Foundation Dérivé de sélénazole ayant un ligand qui active le récepteur activé de la prolifération des peroxysomes (ppar), son procédé de préparation et utilisation des composés chimiques
WO2015035171A1 (fr) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Utilisation d'un agoniste de ppar-delta pour le traitement d'une amyotrophie
WO2023147309A1 (fr) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Utilisation d'agonistes ppar-delta dans le traitement d'une maladie

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
PL331861A1 (en) * 1996-08-19 1999-08-16 Japan Tobacco Inc Derivatives of propionic acid and their application
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US7091225B2 (en) * 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
WO2002100403A1 (fr) * 2001-06-07 2002-12-19 Eli Lilly And Company Modulateurs des recepteurs actives par les proliferateurs du peroxisome (ppar)

Also Published As

Publication number Publication date
EA200400943A1 (ru) 2005-02-24
DE60323060D1 (de) 2008-10-02
OA12780A (en) 2006-07-07
AP2004003124A0 (en) 2004-09-30
PE20030989A1 (es) 2003-11-29
AU2003206059A1 (en) 2003-09-16
EP1482935A1 (fr) 2004-12-08
ATE405260T1 (de) 2008-09-15
IS7377A (is) 2004-07-29
HN2003000090A (es) 2004-05-05
AR038881A1 (es) 2005-02-02
EP1482935B1 (fr) 2008-08-20
ECSP045285A (es) 2004-10-26
TW200305403A (en) 2003-11-01
TNSN04168A1 (fr) 2007-03-12
ES2310650T3 (es) 2009-01-16
CO5601012A2 (es) 2006-01-31
ZA200406068B (en) 2005-09-06
JP2005528348A (ja) 2005-09-22
WO2003074050A1 (fr) 2003-09-12
US20030207924A1 (en) 2003-11-06
PL372969A1 (en) 2005-08-08
UY27695A1 (es) 2003-10-31
CA2478520A1 (fr) 2003-09-12
MXPA04007564A (es) 2004-11-10
NO20044242L (no) 2004-10-06
KR20040091693A (ko) 2004-10-28
PA8567801A1 (es) 2003-11-12
BR0308277A (pt) 2004-12-28

Similar Documents

Publication Publication Date Title
MA27181A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar.
MA27182A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar.
MA27189A1 (fr) Composes qui modulent l'activite de ppar et procedes pour leur preparation
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA26688A1 (fr) 4-carboxamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
AU1850801A (en) The combination of a serotonin reuptake inhibitor and irindalone
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
MA26689A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2
WO2005004802A3 (fr) Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
FR08C0004I2 (fr) Composition orale d' une dose pour une libération prolongée
MA30231B1 (fr) Derives de benzamides et d'heteroarenes
MA26954A1 (fr) ALPHA-ARYLETHANOLAMINES ET LEUR UTILISATION COMME AGONISTES DES RECEPTEURS BeTA3-ADRENERGIQUES
DZ3191A1 (fr) Composés d'indazole et compositions pharmaceutiques inhibant les protéines kinases, et procédés d'utilisation de ceux-ci.
MA27596A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
DZ2752A1 (fr) Composés et compositions pharmaceutiques pour le traitement du paludisme.
MA27135A1 (fr) Agents antidiabetiques oraux
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
MA27141A1 (fr) DERIVES DE 3-AZABICYCLO[3.1.0]HEXANE SERVANT D'ANTAGONISTES DES RECEPTEURS D'OPIOiDES
SE9903997D0 (sv) New compounds
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.